There is not much available information about thenyldiamine, is known, that it is used as antihistamine and for the treatment of asthma and bronchitis.

Amosulalol is a beta- and alpha-1 adrenoceptor-blocking agent developed for the treatment of hypertension. Amosulalol does not cross blood brain barrier and does not have adverse affect on CNS system.The drug is marketed under the name Lowgan in Japan and Korea.

Citicoline (CDP-choline; cytidine 5'-diphosphocholine) is a novel nutrient with a broad spectrum of benefits for conditions associated with symptoms of neurological dysfunction shows promise of clinical efficacy in elderly patients with cognitive deficits, inefficient memory, and early-stage Alzheimer's disease. Citicoline has also been investigated as a therapy in stroke patient. Despite it was approved in some countries for treatment Traumatic Brain Injury (TBI), the use of this drug for acute TBI seems to have no field of support anymore, whereas it may have some benefits in improving the neuro-cognitive state in chronic TBI patients. It's also recommended to keep in mind acute interventions like Psychological First Aid (PFA) during acute TBI management. Citicoline plays several important roles in human physiology, including enhancement of structural integrity and signaling for cell membranes, support of acetylcholine synthesis, and synthesis of betaine, a methyl donor. The precise mechanism of action of Citicoline to treat disease is unknown, but was confirmed, that drug might increase phosphatidylcholine (PtdCho) synthesis and might reverse PtdCho loss. In addition, was shown, that citicoline modulates phospholipids metabolism and neurotransmitter levels and appears to improve cognition in some central nervous system disorders such as bipolar disorder and cocaine dependence. Bipolar disorder is associated with the highest rates of substance abuse of any psychiatric disorder. Cocaine use is particularly common in patients with bipolar disorder.

MK-467 (also known as Vatinoxan) is a peripheral α2 -adrenoceptor antagonist patented by American multinational pharmaceutical company Merck & Co., Inc. for treatment of hypertension, diabetes, obesity, and as blood platelet aggregation. In preclinical models Vatinoxan administration alleviate the unwanted cardiopulmonary effects of various α2-agonists (such as bradycardia, vasoconstriction, and hypoxemia). Because of its low lipophilicity MK-467 poorly penetrates the mammalian central nervous system and preserve the centrally mediated desired effects of α2-agonists. Simultaneous intramuscular injection of MK-467 hastened the absorption of α2-agonist drugs, which was manifested by rapid onset of sedation.

LAURALKONIUM is an antiseptic.